Effect of Physical Therapy on Breast Cancer Related Lymphedema

January 30, 2023 updated by: Valgerdur Hilmarsdottir Gram, Hospital of South West Jutland

Effect of Physical Therapy on Breast Cancer Related Lymphedema; A Multicenter, Randomized, Single-blind, Equivalence Trial

The objective of this study is to investigate if Complete Decongestive Therapy is equally effective whether it includes manual lymphatic drainage or not in the treatment of lymphoedema among patients with breast cancer.

Study Overview

Detailed Description

Physical therapy treatment of patients with lymphoedema includes treatment based on the principles of 'Complete Decongestive Therapy' (CDT). CDT consists of following components; skin care, manual lymphatic drainage, bandaging and exercises. Regarding what type of treatment of treatments is most effective, the scientific evidence is sparse. Studies have focused on the time-consuming manual lymphatic drainage, but the scientific evidence is not consistent.

A randomized, single-blind, equivalence trial. A total of 160 breast cancer patients with lymphoedema will be recruited from 3 hospitals and randomised into one of two treatment groups: A: Complete Decongestive TherapyA (incl. manual drainage) or B: Complete Decongestive TherapyB (except manual lymphatic drainage

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Region Of Southern Denmark
      • Esbjerg, Region Of Southern Denmark, Denmark, 6700
        • Hospital of Southwest Denmark
      • Odense, Region Of Southern Denmark, Denmark, 5000
        • Department of Rehabilitation, Odense University Hospital
      • Vejle, Region Of Southern Denmark, Denmark, 7000
        • Department of Physical Therapy, Lillebaelt Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • The diagnose breast cancer regardless of date for operation and identified lymphoedema
  • Precede ultrasonic scanning of axilla in order to exclude local relapse
  • Lymphoedema > 2 cm i.e. stage II-III
  • Completed radiotherapy and/or chemotherapy at least 2 months prior inclusion

Exclusion Criteria:

  • Relapse of breast cancer
  • Untreated infection
  • Untreated heart failure
  • Untreated renal failure
  • Untreated deep venous thrombosis in the arm
  • Unable to participate in physiotherapy treatment and/or not able to understand instructions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Physical TherapyB
Group B

Group A:

  • Skin care
  • Manual lymphatic drainage
  • Bandaging using Coban™2Lite
  • Guidance on physical activity
PLACEBO_COMPARATOR: Physical TherapyA
Group A

Group B:

  • Skin care
  • Bandaging using Coban™2Lite
  • Guidance on physical activity

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The percentage volume reduction of lymphoedema (%)
Time Frame: 7 months
7 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences in circumference of the arm (composite outcome measure), bodyweight, patient sensation of heaviness, patient sensation of tension, and quality of life
Time Frame: 7 months
Circumference of the arm consists of 7 measurements but these will be converted to one outcome measure when estimating the difference between baseline and post intervention measurements
7 months

Other Outcome Measures

Outcome Measure
Time Frame
Percentage volume reduction of lymphedema (%) from baseline to week 4. Percentage volume reduction of lymphedema (%) from week 4 to week 7
Time Frame: 7 months
7 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Bibi Gram, PhD, THe Hospital of Southwest Denmark

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (ACTUAL)

September 1, 2017

Study Completion (ACTUAL)

September 1, 2017

Study Registration Dates

First Submitted

December 3, 2013

First Submitted That Met QC Criteria

December 13, 2013

First Posted (ESTIMATE)

December 19, 2013

Study Record Updates

Last Update Posted (ACTUAL)

January 31, 2023

Last Update Submitted That Met QC Criteria

January 30, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Physical TherapyA

3
Subscribe